Хронічні лімфопроліферативні захворювання та кардіоваскулярний ризик (огляд літератури)

Автор(и)

DOI:

https://doi.org/10.14739/2310-1210.2022.5.266062

Ключові слова:

серцево-судинні події, кардіотоксичність, поліхімієтерапія, діагностика, прогностичні фактори

Анотація

Порушення функції серця у разі призначення протипухлинних препаратів можуть обмежувати лікування хронічних лімфопроліферативних захворювань (ХЛПЗ). Кардіоваскулярна токсичність, пов’язана з протипухлинним лікуванням, включає гіпертензію, гіпотензію, аритмії, перикардит, порушення проведення, тромбоемболічні ускладнення, серцеву недостатність і смерть. Ризик розвитку кардіотоксичності збільшують деякі фактори, як-от ступінь експозиції препарату, вік, захворювання серця в анамнезі, артеріальна гіпертензія, комбінована терапія, попередні променева чи хімієтерапія.

Мета роботи – оцінити вплив протипухлинного лікування на виникнення кардіоваскулярних подій у хворих на ХЛПЗ за відомостями світової наукової літератури.

Принциповим є виявлення ознак кардіоваскулярної токсичності до розвитку клінічних проявів пошкодження міокарда та судин. Залишається нез’ясованою роль маркерів у виявленні групи ризику несприятливих кардіоваскулярних подій. Рання діагностика та визначення прогностичних факторів кардіоваскулярної токсичності, що розвиваються після поліхімієтерапії онкогематологічних захворювань, – важливі та до кінця не з’ясовані завдання.

Висновки. Прогноз розвитку кардіоваскулярних подій після протипухлинного лікування ХЛПЗ залишається несприятливим. Протягом протипухлинного лікування для виявлення ранніх ознак і ризику виникнення кардіотоксичності рекомендований клінічний моніторинг, застосування методів візуалізації, визначення рівня біомаркерів (натрійуретичні пептиди, тропоніни) для стратифікації ризику кардіотоксичності. Застосування новітніх біомаркерів та їхніх комбінацій може бути шляхом покращення оцінювання ризику кардіотоксичності під час ХЛПЗ. Нині немає достатніх доказів доцільності рутинного визначення цих біомаркерів, що вказує на необхідність планування нових досліджень.

Біографії авторів

Б. Б. Самура, Запорізький державний медичний університет, Україна

д-р мед. наук, професор каф. внутрішніх хвороб 3

М. О. Панасенко, Запорізький державний медичний університет, Україна

очний аспірант каф. внутрішніх хвороб 3

Посилання

Novak, V. L., Masliak, Z. V., Klymenko, S. V., Voitsitskyi, Yu. V., Bereketa, Ya. D., Prymak, S. V., & Hutor, T. H. (2017). Pokaznyky diialnosti hematolohichnoi sluzhby Ukrainy v 2016 rotsi [Performance indicators of the hematology service of Ukraine in 2016]. Lviv, 2017, 44. [in Ukrainian].

Ukrainian cancer registry statistics. (2019). Rak v Ukraini, 2017-2018. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby [Cancer in Ukraine, 2017-2018. Occupation, death, demonstration of oncological service]. Bulletin of National Cancer Registry of Ukraine, 20. [in Ukrainian].

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660

Ewer, M. S., & Ewer, S. M. (2015). Cardiotoxicity of anticancer treatments. Nature reviews. Cardiology, 12(9), 547-558. https://doi.org/10.1038/nrcardio.2015.65

Kryachok, I. A., & Tytorenko, I. B. (2014). Kardiotoksychnist pry provedenni khimioterapevtychnoho likuvannia u patsiientiv pokhyloho viku iz nekhodzhkinskymy limfomamy [Chemotherapy-related cardiotoxicity in elderly patients with non-Hodgkin lymphoma]. Klinicheskaya onkologiya, (1), 69-73. [in Ukrainian].

Tseluiko, V. Y., & Radchenko, O. V. (2018). Serdechno-sosudistye zabolevaniya u onkologicheskikh bolnykh. Liky Ukrainy, (3), 7-20. [in Russian].

Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., Moslehi, J., … ESC Scientific Document Group (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal, ehac244. Advance online publication. https://doi.org/10.1093/eurheartj/ehac244

Gilchrist, S. C., Barac, A., Ades, P. A., Alfano, C. M., Franklin, B. A., Jones, L. W., La Gerche, A., Ligibel, J. A., Lopez, G., Madan, K., Oeffinger, K. C., Salamone, J., Scott, J. M., Squires, R. W., Thomas, R. J., Treat-Jacobson, D. J., Wright, J. S., & American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease (2019). Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation, 139(21), e997-e1012. https://doi.org/10.1161/CIR.0000000000000679

Vatutin, N. T., Sklyanaya, E. V., Shevelek, A. N., Smirnova, A. S., El'-Khatib, M. A., Gritsenko, Yu. P., Kolesnikov, V. S., & Taratorina, A. A. (2017). Preparaty, vyzyvayushchie ili ukhudshayushchie techenie serdechnoi nedostatochnosti. Obzor rekomendatsii Amerikanskoi assotsiatsii serdtsa [Drugs that cause or worsen heart failure. Review of American Heart Association Guidelines]. Praktychna anhiolohiia, (1), 52-56. [in Russian].

Kevane, B., Crowley, M. P., Bolster, M., & Gilligan, O. (2014). Myeloma relapse involving the heart and presenting as acute cardiac failure. Journal of clinical oncology, 32(18), e67-e68. https://doi.org/10.1200/JCO.2012.47.6713

Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Wimperis, J., Culligan, D., Popova, B., Smith, P., McMillan, A., Brownell, A., Kruger, A., Lister, A., Hoskin, P., O'Doherty, M., & Barrington, S. (2015). Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. The New England journal of medicine, 372(17), 1598-1607. https://doi.org/10.1056/NEJMoa1408648

Schaapveld, M., Aleman, B. M., van Eggermond, A. M., Janus, C. P., Krol, A. D., van der Maazen, R. W., Roesink, J., Raemaekers, J. M., de Boer, J. P., Zijlstra, J. M., van Imhoff, G. W., Petersen, E. J., Poortmans, P. M., Beijert, M., Lybeert, M. L., Mulder, I., Visser, O., Louwman, M. W., Krul, I. M., Lugtenburg, P. J., … van Leeuwen, F. E. (2015). Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. The New England journal of medicine, 373(26), 2499-2511. https://doi.org/10.1056/NEJMoa1505949

De Luca, V., Gallio, E., Bartoncini, S., Giglioli, F. R., Sardo, A., Cavallin, C., Iorio, G. C., Orlandi, E., Parise, R., Palladino, C., Buonavita, A., Fiandra, C., Levis, M., & Ricardi, U. (2021). Adoption of Expansion Margins to Reduce the Dose Received by the Coronary Arteries and the Risk of Cardiovascular Events in Lymphoma Patients. Practical radiation oncology, 11(1), 66-73. https://doi.org/10.1016/j.prro.2020.06.005

Gevaert, S. A., Halvorsen, S., Sinnaeve, P. R., Sambola, A., Gulati, G., Lancellotti, P., Van Der Meer, P., Lyon, A. R., Farmakis, D., Lee, G., Boriani, G., Wechalekar, A., Okines, A., & Asteggiano, R. (2021). Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. European heart journal. Acute cardiovascular care, 10(8), 947-959. https://doi.org/10.1093/ehjacc/zuab056

van Nimwegen, F. A., Schaapveld, M., Janus, C. P., Krol, A. D., Petersen, E. J., Raemaekers, J. M., Kok, W. E., Aleman, B. M., & van Leeuwen, F. E. (2015). Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA internal medicine, 175(6), 1007-1017. https://doi.org/10.1001/jamainternmed.2015.1180

van Nimwegen, F. A., Schaapveld, M., Cutter, D. J., Janus, C. P., Krol, A. D., Hauptmann, M., Kooijman, K., Roesink, J., van der Maazen, R., Darby, S. C., Aleman, B. M., & van Leeuwen, F. E. (2016). Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. Journal of clinical oncology, 34(3), 235-243. https://doi.org/10.1200/JCO.2015.63.4444

Akazawa H. (2017). [Cardiotoxicity of Cancer Chemotherapy - Mechanisms and Therapeutic Approach]. Cancer & chemotherapy, 44(13), 2058-2063.

Rokyta, O. I., & Rudenko, Yu. V. (2017). Likuvannia onkolohichnykh zakhvoriuvan i sertsevo-sudynna toksychnist. Tochka zoru Yevropeiskoho tovarystva kardiolohiv. Chastyna I [Treatment of oncological diseases and cardiovascular toxicity. Viewpoint of the European Society of Cardiology. Part 1]. Sertse i sudyny, (2), 11-19. [in Ukrainian].

Bahia, L., de Aguiar, L. G., Villela, N. R., Bottino, D., & Bouskela, E. (2006). O endotélio na síndrome metabólica [The endothelium in the metabolic syndrome]. Arquivos brasileiros de endocrinologia e metabologia, 50(2), 291-303. https://doi.org/10.1590/s0004-27302006000200015

Suter, T. M., & Ewer, M. S. (2013). Cancer drugs and the heart: importance and management. European heart journal, 34(15), 1102-1111. https://doi.org/10.1093/eurheartj/ehs181

Skrypnyk, I. M., Maslova, H. S., & Lymanets, T. V. (2016). Ishemichna khvoroba sertsia yak faktor ryzyku antratsyklinindukovanoi kardiotoksychnosti [Ischemic heart disease as a risk factor for anthracycline-induced cardiotoxicity]. Vrachebnoe delo, (5-6), 47-52. [in Ukrainian].

Gulati, A., Jabbour, A., Ismail, T. F., Guha, K., Khwaja, J., Raza, S., Morarji, K., Brown, T. D., Ismail, N. A., Dweck, M. R., Di Pietro, E., Roughton, M., Wage, R., Daryani, Y., O'Hanlon, R., Sheppard, M. N., Alpendurada, F., Lyon, A. R., Cook, S. A., Cowie, M. R., … Prasad, S. K. (2013). Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA, 309(9), 896-908. https://doi.org/10.1001/jama.2013.1363

Khouri, M. G., Douglas, P. S., Mackey, J. R., Martin, M., Scott, J. M., Scherrer-Crosbie, M., & Jones, L. W. (2012). Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation, 126(23), 2749-2763. https://doi.org/10.1161/CIRCULATIONAHA.112.100560

Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., Jerusalem, G., … Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European heart journal. Cardiovascular Imaging, 15(10), 1063-1093. https://doi.org/10.1093/ehjci/jeu192

Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., Suter, T. M., & ESC Scientific Document Group (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European heart journal, 37(36), 2768-2801. https://doi.org/10.1093/eurheartj/ehw211

Lyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., Tocchetti, C. G., Moslehi, J. J., Groarke, J. D., Bergler-Klein, J., Khoo, V., Tan, L. L., Anker, M. S., von Haehling, S., Maack, C., Pudil, R., Barac, A., Thavendiranathan, P., Ky, B., Neilan, T. G., … Lenihan, D. (2020). Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European journal of heart failure, 22(11), 1945-1960. https://doi.org/10.1002/ejhf.1920

Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., Fiorentini, C., & Cipolla, C. M. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation, 131(22), 1981-1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777

Wang, L., Tan, T. C., Halpern, E. F., Neilan, T. G., Francis, S. A., Picard, M. H., Fei, H., Hochberg, E. P., Abramson, J. S., Weyman, A. E., Kuter, I., & Scherrer-Crosbie, M. (2015). Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. The American journal of cardiology, 116(3), 442-446. https://doi.org/10.1016/j.amjcard.2015.04.064

Armenian, S. H., Hudson, M. M., Mulder, R. L., Chen, M. H., Constine, L. S., Dwyer, M., Nathan, P. C., Tissing, W. J., Shankar, S., Sieswerda, E., Skinner, R., Steinberger, J., van Dalen, E. C., van der Pal, H., Wallace, W. H., Levitt, G., Kremer, L. C., & International Late Effects of Childhood Cancer Guideline Harmonization Group (2015). Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet. Oncology, 16(3), e123-e136. https://doi.org/10.1016/S1470-2045(14)70409-7

Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., Suter, T. M., Zamorano, J. L., Aboyans, V., Achenbach, S., Agewall, S., … Document Reviewers (2017). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European journal of heart failure, 19(1), 9-42. https://doi.org/10.1002/ejhf.654

Askolskyi, A. V., Sivak, L. A., Zharinov, O. I., Antomonov, M. Y., & Shevchuk, L. A. (2017). Profilaktyka rannoi antratsyklin-indukovanoi kardiotoksychnosti polikhimioterapii u khvorykh na rak hrudnoi zalozy [Prevention of early anthracycline-induced cardiotoxicity in patients with breast cancer]. Klinicheskaya onkologiya, (1), 45-50. [in Ukrainian].

Drafts, B. C., Twomley, K. M., D'Agostino, R., Jr, Lawrence, J., Avis, N., Ellis, L. R., Thohan, V., Jordan, J., Melin, S. A., Torti, F. M., Little, W. C., Hamilton, C. A., & Hundley, W. G. (2013). Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC. Cardiovascular imaging, 6(8), 877-885. https://doi.org/10.1016/j.jcmg.2012.11.017

Gribben, J. G., Bosch, F., Cymbalista, F., Geisler, C. H., Ghia, P., Hillmen, P., Moreno, C., & Stilgenbauer, S. (2018). Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. British journal of haematology, 180(5), 666-679. https://doi.org/10.1111/bjh.15080

Dickerson, T., Wiczer, T., Waller, A., Philippon, J., Porter, K., Haddad, D., Guha, A., Rogers, K. A., Bhat, S., Byrd, J. C., Woyach, J. A., Awan, F., & Addison, D. (2019). Hypertension and incident cardiovascular events following ibrutinib initiation. Blood, 134(22), 1919-1928. https://doi.org/10.1182/blood.2019000840

Salem, J. E., Manouchehri, A., Bretagne, M., Lebrun-Vignes, B., Groarke, J. D., Johnson, D. B., Yang, T., Reddy, N. M., Funck-Brentano, C., Brown, J. R., Roden, D. M., & Moslehi, J. J. (2019). Cardiovascular Toxicities Associated With Ibrutinib. Journal of the American College of Cardiology, 74(13), 1667-1678. https://doi.org/10.1016/j.jacc.2019.07.056

Byrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O'Brien, S., Yenerel, M. N., Illés, A., Kay, N., Garcia-Marco, J. A., Mato, A., Pinilla-Ibarz, J., Seymour, J. F., Lepretre, S., Stilgenbauer, S., Robak, T., Rothbaum, W., Izumi, R., Hamdy, A., … Jurczak, W. (2021). Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of clinical oncology, 39(31), 3441-3452. https://doi.org/10.1200/JCO.21.01210

Brown, J. R., Byrd, J. C., Ghia, P., Sharman, J. P., Hillmen, P., Stephens, D. M., Sun, C., Jurczak, W., Pagel, J. M., Ferrajoli, A., Patel, P., Tao, L., Kuptsova-Clarkson, N., Moslehi, J., & Furman, R. R. (2022). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica, 107(6), 1335-1346. https://doi.org/10.3324/haematol.2021.278901

Svennberg, E., Tjong, F., Goette, A., Akoum, N., Di Biase, L., Bordachar, P., Boriani, G., Burri, H., Conte, G., Deharo, J. C., Deneke, T., Drossart, I., Duncker, D., Han, J. K., Heidbuchel, H., Jais, P., de Oliviera Figueiredo, M. J., Linz, D., Lip, G., Malaczynska-Rajpold, K., … Sinner, M. (2022). How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace, 24(6), 979-1005. https://doi.org/10.1093/europace/euac038

Abdel-Qadir, H., Sabrie, N., Leong, D., Pang, A., Austin, P. C., Prica, A., Nanthakumar, K., Calvillo-Argüelles, O., Lee, D. S., & Thavendiranathan, P. (2021). Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. Journal of clinical oncology, 39(31), 3453-3462. https://doi.org/10.1200/JCO.21.00693

Waxman, A. J., Clasen, S., Hwang, W. T., Garfall, A., Vogl, D. T., Carver, J., O'Quinn, R., Cohen, A. D., Stadtmauer, E. A., Ky, B., & Weiss, B. M. (2018). Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA oncology, 4(3), e174519. https://doi.org/10.1001/jamaoncol.2017.4519

Siegel, D., Martin, T., Nooka, A., Harvey, R. D., Vij, R., Niesvizky, R., Badros, A. Z., Jagannath, S., McCulloch, L., Rajangam, K., & Lonial, S. (2013). Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica, 98(11), 1753-1761. https://doi.org/10.3324/haematol.2013.089334

Cornell, R. F., Ky, B., Weiss, B. M., Dahm, C. N., Gupta, D. K., Du, L., Carver, J. R., Cohen, A. D., Engelhardt, B. G., Garfall, A. L., Goodman, S. A., Harrell, S. L., Kassim, A. A., Jadhav, T., Jagasia, M., Moslehi, J., O'Quinn, R., Savona, M. R., Slosky, D., Smith, A., … Lenihan, D. (2019). Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. Journal of clinical oncology, 37(22), 1946-1955. https://doi.org/10.1200/JCO.19.00231

Fakhri, B., Fiala, M. A., Shah, N., Vij, R., & Wildes, T. M. (2020). Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database. Cancer, 126(4), 808-813. https://doi.org/10.1002/cncr.32601

Mancuso, S., Carlisi, M., Sarocchi, M., Napolitano, M., & Siragusa, S. (2018). Cardio-oncology in multiple myeloma: is it time for a specific focus?. Leukemia & lymphoma, 59(7), 1764-1766. https://doi.org/10.1080/10428194.2017.1393674

Danhof, S., Schreder, M., Rasche, L., Strifler, S., Einsele, H., & Knop, S. (2016). 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors. European journal of haematology, 97(1), 25-32. https://doi.org/10.1111/ejh.12677

Gavazzoni, M., Lombardi, C. M., Vizzardi, E., Gorga, E., Sciatti, E., Rossi, L., Belotti, A., Rossi, G., Metra, M., & Raddino, R. (2018). Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. European journal of pharmacology, 838, 85-90. https://doi.org/10.1016/j.ejphar.2018.09.014

Fradley, M. G., Groarke, J. D., Laubach, J., Alsina, M., Lenihan, D. J., Cornell, R. F., Maglio, M., Shain, K. H., Richardson, P. G., & Moslehi, J. (2018). Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. British journal of haematology, 180(2), 271-275. https://doi.org/10.1111/bjh.14970

Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., … ASPIRE Investigators (2015). Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. The New England journal of medicine, 372(2), 142-152. https://doi.org/10.1056/NEJMoa1411321

Willis, M. S., & Patterson, C. (2013). Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart?. The New England journal of medicine, 368(5), 455-464. https://doi.org/10.1056/NEJMra1106180

Castel, M., Despas, F., Modesto, A., Gales, C., Honton, B., Galinier, M., Senard, J. M., & Pathak, A. (2013). Effets indésirables cardiaques des chimiothérapies [Cardiotoxicity of chemotherapies]. Presse medicale, 42(1), 26-39. https://doi.org/10.1016/j.lpm.2012.04.014

Nesen, A. O. (2014). Khronichni neinfektsiini zakhvoriuvannia: aktsent na komorbidnist i pidvyshchenyi kardiovasuliarnyi ryzyk [Chronic noncommunicable diseases: emphasis on comorbidity and increased cardiovascular risk]. Ukrainskyi terapevtychnyi zhurnal, 2, 26-32. [in Ukrainian].

Lancellotti, P., Suter, T. M., López-Fernández, T., Galderisi, M., Lyon, A. R., Van der Meer, P., Cohen Solal, A., Zamorano, J. L., Jerusalem, G., Moonen, M., Aboyans, V., Bax, J. J., & Asteggiano, R. (2019). Cardio-Oncology Services: rationale, organization, and implementation. European heart journal, 40(22), 1756-1763. https://doi.org/10.1093/eurheartj/ehy453

Jaworski, C., Mariani, J. A., Wheeler, G., & Kaye, D. M. (2013). Cardiac complications of thoracic irradiation. Journal of the American College of Cardiology, 61(23), 2319-2328. https://doi.org/10.1016/j.jacc.2013.01.090

Vydyborets, S. V., Hartovska, I. R., Borysenko, Ye. O., & Maiko, O. V. Markery endohennoi intoksykatsii ta infuziino-transfuziina terapiia khvorykh na hostri leikozy v protsesi intensyvnoi khimioterapii [Markers of endogenous intoxication and infusion-transfusion therapy of patients with hostile leukemia during intensive chemotherapy]. Semeinaya meditsina, (6), 111-114. [in Ukrainian].

Visseren, F., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J. M., Capodanno, D., Cosyns, B., Crawford, C., Davos, C. H., Desormais, I., Di Angelantonio, E., Franco, O. H., Halvorsen, S., Hobbs, F., Hollander, M., Jankowska, E. A., … ESC Scientific Document Group (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European heart journal, 42(34), 3227-3337. https://doi.org/10.1093/eurheartj/ehab484

Chow, E. J., Chen, Y., Kremer, L. C., Breslow, N. E., Hudson, M. M., Armstrong, G. T., Border, W. L., Feijen, E. A., Green, D. M., Meacham, L. R., Meeske, K. A., Mulrooney, D. A., Ness, K. K., Oeffinger, K. C., Sklar, C. A., Stovall, M., van der Pal, H. J., Weathers, R. E., Robison, L. L., & Yasui, Y. (2015). Individual prediction of heart failure among childhood cancer survivors. Journal of clinical oncology, 33(5), 394-402. https://doi.org/10.1200/JCO.2014.56.1373

Szmit, S., Jurczak, W., Zaucha, J. M., Drozd-Sokołowska, J., Spychałowicz, W., Joks, M., Długosz-Danecka, M., & Torbicki, A. (2014). Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. Journal of the American Society of Hypertension : JASH, 8(11), 791-799. https://doi.org/10.1016/j.jash.2014.08.009

Armstrong, G. T., Oeffinger, K. C., Chen, Y., Kawashima, T., Yasui, Y., Leisenring, W., Stovall, M., Chow, E. J., Sklar, C. A., Mulrooney, D. A., Mertens, A. C., Border, W., Durand, J. B., Robison, L. L., & Meacham, L. R. (2013). Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. Journal of clinical oncology, 31(29), 3673-3680. https://doi.org/10.1200/JCO.2013.49.3205

Lancellotti, P., Nkomo, V. T., Badano, L. P., Bergler-Klein, J., Bogaert, J., Davin, L., Cosyns, B., Coucke, P., Dulgheru, R., Edvardsen, T., Gaemperli, O., Galderisi, M., Griffin, B., Heidenreich, P. A., Nieman, K., Plana, J. C., Port, S. C., Scherrer-Crosbie, M., Schwartz, R. G., Sebag, I. A., … Society of Cardiovascular Computed Tomography (2013). Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. European heart journal. Cardiovascular Imaging, 14(8), 721-740. https://doi.org/10.1093/ehjci/jet123

Lang, R. M., Badano, L. P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., Flachskampf, F. A., Foster, E., Goldstein, S. A., Kuznetsova, T., Lancellotti, P., Muraru, D., Picard, M. H., Rietzschel, E. R., Rudski, L., Spencer, K. T., Tsang, W., & Voigt, J. U. (2015). Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 28(1), 1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003

Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., Zamorano, J. L., … ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2020). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of oncology, 31(2), 171-190. https://doi.org/10.1016/j.annonc.2019.10.023

Čelutkienė, J., Pudil, R., López-Fernández, T., Grapsa, J., Nihoyannopoulos, P., Bergler-Klein, J., Cohen-Solal, A., Farmakis, D., Tocchetti, C. G., von Haehling, S., Barberis, V., Flachskampf, F. A., Čeponienė, I., Haegler-Laube, E., Suter, T., Lapinskas, T., Prasad, S., de Boer, R. A., Wechalekar, K., Anker, M. S., … Lyon, A. R. (2020). Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). European journal of heart failure, 22(9), 1504-1524. https://doi.org/10.1002/ejhf.1957

Hoffmann, R., Barletta, G., von Bardeleben, S., Vanoverschelde, J. L., Kasprzak, J., Greis, C., & Becher, H. (2014). Analysis of left ventricular volumes and function: a multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhanced and contrast-enhanced two-dimensional and three-dimensional echocardiography. Journal of the American Society of Echocardiography, 27(3), 292-301. https://doi.org/10.1016/j.echo.2013.12.005

van Kalsbeek, R. J., Mulder, R. L., Skinner, R., & Kremer, L. (2021). The Concept of Cancer Survivorship and Models for Long-Term Follow-Up. Frontiers of hormone research, 54, 1-15. https://doi.org/10.1159/000514693

Thavendiranathan, P., Negishi, T., Coté, M. A., Penicka, M., Massey, R., Cho, G. Y., Hristova, K., Vinereanu, D., Popescu, B. A., Izumo, M., Negishi, K., Marwick, T. H., & SUCCOUR Investigators (2018). Single Versus Standard Multiview Assessment of Global Longitudinal Strain for the Diagnosis of Cardiotoxicity During Cancer Therapy. JACC. Cardiovascular imaging, 11(8), 1109-1118. https://doi.org/10.1016/j.jcmg.2018.03.003

Oikonomou, E. K., Kokkinidis, D. G., Kampaktsis, P. N., Amir, E. A., Marwick, T. H., Gupta, D., & Thavendiranathan, P. (2019). Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA cardiology, 4(10), 1007-1018. https://doi.org/10.1001/jamacardio.2019.2952

Cheng, S., Larson, M. G., McCabe, E. L., Osypiuk, E., Lehman, B. T., Stanchev, P., Aragam, J., Benjamin, E. J., Solomon, S. D., & Vasan, R. S. (2013). Reproducibility of speckle-tracking-based strain measures of left ventricular function in a community-based study. Journal of the American Society of Echocardiography, 26(11), 1258-1266.e2. https://doi.org/10.1016/j.echo.2013.07.002

Thavendiranathan, P., Poulin, F., Lim, K. D., Plana, J. C., Woo, A., & Marwick, T. H. (2014). Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. Journal of the American College of Cardiology, 63(25 Pt A), 2751-2768. https://doi.org/10.1016/j.jacc.2014.01.073

Tsai, H. R., Gjesdal, O., Wethal, T., Haugaa, K. H., Fosså, A., Fosså, S. D., & Edvardsen, T. (2011). Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. The American journal of cardiology, 107(3), 472-477. https://doi.org/10.1016/j.amjcard.2010.09.048

Mawad, W., & Friedberg, M. K. (2017). The continuing challenge of evaluating diastolic function by echocardiography in children: developing concepts and newer modalities. Current opinion in cardiology, 32(1), 93-100. https://doi.org/10.1097/HCO.0000000000000346

Voigt, J. U., Pedrizzetti, G., Lysyansky, P., Marwick, T. H., Houle, H., Baumann, R., Pedri, S., Ito, Y., Abe, Y., Metz, S., Song, J. H., Hamilton, J., Sengupta, P. P., Kolias, T. J., d'Hooge, J., Aurigemma, G. P., Thomas, J. D., & Badano, L. P. (2015). Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. European heart journal. Cardiovascular Imaging, 16(1), 1-11. https://doi.org/10.1093/ehjci/jeu184

Herrmann, J., Lenihan, D., Armenian, S., Barac, A., Blaes, A., Cardinale, D., Carver, J., Dent, S., Ky, B., Lyon, A. R., López-Fernández, T., Fradley, M. G., Ganatra, S., Curigliano, G., Mitchell, J. D., Minotti, G., Lang, N. N., Liu, J. E., Neilan, T. G., Nohria, A., … Valent, P. (2022). Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European heart journal, 43(4), 280-299. https://doi.org/10.1093/eurheartj/ehab674

Thavendiranathan, P., Grant, A. D., Negishi, T., Plana, J. C., Popović, Z. B., & Marwick, T. H. (2013). Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. Journal of the American College of Cardiology, 61(1), 77-84. https://doi.org/10.1016/j.jacc.2012.09.035

Houbois, C. P., Nolan, M., Somerset, E., Shalmon, T., Esmaeilzadeh, M., Lamacie, M. M., Amir, E., Brezden-Masley, C., Koch, C. A., Thevakumaran, Y., Yan, A. T., Marwick, T. H., Wintersperger, B. J., & Thavendiranathan, P. (2021). Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography. JACC. Cardiovascular imaging, 14(5), 962-974. https://doi.org/10.1016/j.jcmg.2020.09.039

Armstrong, G. T., Plana, J. C., Zhang, N., Srivastava, D., Green, D. M., Ness, K. K., Daniel Donovan, F., Metzger, M. L., Arevalo, A., Durand, J. B., Joshi, V., Hudson, M. M., Robison, L. L., & Flamm, S. D. (2012). Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. Journal of clinical oncology, 30(23), 2876-2884. https://doi.org/10.1200/JCO.2011.40.3584

Phillips, W. J., Johnson, C., Law, A., Turek, M., Small, A. R., Dent, S., Ruddy, T. D., Beanlands, R. S., Chow, B., & Small, G. R. (2019). Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events. International journal of cardiology, 289, 138-143. https://doi.org/10.1016/j.ijcard.2019.01.056

Porta-Sánchez, A., Gilbert, C., Spears, D., Amir, E., Chan, J., Nanthakumar, K., & Thavendiranathan, P. (2017). Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. Journal of the American Heart Association, 6(12), e007724. https://doi.org/10.1161/JAHA.117.007724

Praga, C., Beretta, G., Vigo, P. L., Lenaz, G. R., Pollini, C., Bonadonna, G., Canetta, R., Castellani, R., Villa, E., Gallagher, C. G., von Melchner, H., Hayat, M., Ribaud, P., De Wasch, G., Mattsson, W., Heinz, R., Waldner, R., Kolaric, K., Buehner, R., Ten Bokkel-Huyninck, W., … Mayr, A. C. (1979). Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer treatment reports, 63(5), 827-834.

Salem, J. E., Nguyen, L. S., Moslehi, J. J., Ederhy, S., Lebrun-Vignes, B., Roden, D. M., Funck-Brentano, C., & Gougis, P. (2021). Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. European heart journal, 42(38), 3915-3928. https://doi.org/10.1093/eurheartj/ehab362

Lentz, R., Feinglass, J., Ma, S., & Akhter, N. (2019). Risk factors for the development of atrial fibrillation on ibrutinib treatment. Leukemia & lymphoma, 60(6), 1447-1453. https://doi.org/10.1080/10428194.2018.1533129

Singla, A., Hogan, W. J., Ansell, S. M., Buadi, F. K., Dingli, D., Dispenzieri, A., Gastineau, D. A., Gertz, M. A., Hayman, S. R., Inwards, D. J., Johnston, P. B., Lacy, M. Q., Litzow, M. R., Micallef, I. N., Porrata, L. F., & Kumar, S. K. (2013). Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biology of blood and marrow transplantation, 19(8), 1233-1237. https://doi.org/10.1016/j.bbmt.2013.05.019

Berezin, A. E. (2015). Biologicheskie markery v diagnostike, prognozirovanii i otsenke effektivnosti terapii serdechnoi nedostatochnosti s sokhranennoi i snizhennoi kontraktil'noi funktsiei [Biological markers in the diagnosis, prognosis and evaluation of the effectiveness of therapy for heart failure with preserved and reduced contractile function]. Sertseva nedostatnist, (2), 16-27. [in Russian].

Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T. M., Ky, B., Štěrba, M., Cardinale, D., Cohen-Solal, A., Tocchetti, C. G., Farmakis, D., Bergler-Klein, J., Anker, M. S., Von Haehling, S., Belenkov, Y., … Lyon, A. R. (2020). Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European journal of heart failure, 22(11), 1966-1983. https://doi.org/10.1002/ejhf.2017

Michel, L., Mincu, R. I., Mahabadi, A. A., Settelmeier, S., Al-Rashid, F., Rassaf, T., & Totzeck, M. (2020). Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. European journal of heart failure, 22(2), 350-361. https://doi.org/10.1002/ejhf.1631

Xue, K., Gu, J. J., Zhang, Q., Liu, X., Wang, J., Li, X. Q., Luo, J., Hernandez-Ilizaliturri, F. J., Fernandez, S. F., Czuczman, M. S., Cao, J., Hong, X., & Guo, Y. (2016). Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial. Oncotarget, 7(22), 32519-32531. https://doi.org/10.18632/oncotarget.8685

Mueller, C., McDonald, K., de Boer, R. A., Maisel, A., Cleland, J., Kozhuharov, N., Coats, A., Metra, M., Mebazaa, A., Ruschitzka, F., Lainscak, M., Filippatos, G., Seferovic, P. M., Meijers, W. C., Bayes-Genis, A., Mueller, T., Richards, M., Januzzi, J. L., Jr, & Heart Failure Association of the European Society of Cardiology (2019). Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European journal of heart failure, 21(6), 715-731. https://doi.org/10.1002/ejhf.1494

Pavo, N., Raderer, M., Hülsmann, M., Neuhold, S., Adlbrecht, C., Strunk, G., Goliasch, G., Gisslinger, H., Steger, G. G., Hejna, M., Köstler, W., Zöchbauer-Müller, S., Marosi, C., Kornek, G., Auerbach, L., Schneider, S., Parschalk, B., Scheithauer, W., Pirker, R., Drach, J., … Pacher, R. (2015). Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart (British Cardiac Society), 101(23), 1874-1880. https://doi.org/10.1136/heartjnl-2015-307848

López-Sendón, J., Álvarez-Ortega, C., Zamora Auñon, P., Buño Soto, A., Lyon, A. R., Farmakis, D., Cardinale, D., Canales Albendea, M., Feliu Batlle, J., Rodríguez Rodríguez, I., Rodríguez Fraga, O., Albaladejo, A., Mediavilla, G., González-Juanatey, J. R., Martínez Monzonis, A., Gómez Prieto, P., González-Costello, J., Serrano Antolín, J. M., Cadenas Chamorro, R., & López Fernández, T. (2020). Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. European heart journal, 41(18), 1720-1729. https://doi.org/10.1093/eurheartj/ehaa006

Beer, L. A., Kossenkov, A. V., Liu, Q., Luning Prak, E., Domchek, S., Speicher, D. W., & Ky, B. (2016). Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction. Circulation research, 119(10), 1135-1144. https://doi.org/10.1161/CIRCRESAHA.116.309004

Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010). Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology, 55(3), 213-220. https://doi.org/10.1016/j.jacc.2009.03.095

Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Laverdière, C., Michon, B., Schorin, M. A., & Sallan, S. E. (2012). Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. Journal of clinical oncology, 30(10), 1042-1049. https://doi.org/10.1200/JCO.2010.30.3404

Loar, R. W., Noel, C. V., Tunuguntla, H., Colquitt, J. L., & Pignatelli, R. H. (2018). State of the art review: Chemotherapy-induced cardiotoxicity in children. Congenital heart disease, 13(1), 5-15. https://doi.org/10.1111/chd.12564

Vianello, E., Dozio, E., Tacchini, L., Frati, L., & Corsi Romanelli, M. M. (2019). ST2/IL-33 signaling in cardiac fibrosis. The international journal of biochemistry & cell biology, 116, 105619. https://doi.org/10.1016/j.biocel.2019.105619

Aula, H., Skyttä, T., Tuohinen, S., Luukkaala, T., Hämäläinen, M., Virtanen, V., Raatikainen, P., Moilanen, E., & Kellokumpu-Lehtinen, P. L. (2020). ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast (Edinburgh, Scotland), 49, 183-186. https://doi.org/10.1016/j.breast.2019.12.001

Frères, P., Bouznad, N., Servais, L., Josse, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC cancer, 18(1), 102. https://doi.org/10.1186/s12885-018-4015-4

Huang, G., Zhai, J., Huang, X., & Zheng, D. (2018). Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy. Medicine, 97(38), e12447. https://doi.org/10.1097/MD.0000000000012447

Samura, B., & Panasenko, M. (2022). SST2 AS a predictor of statin treatment efficacy in patients with multiple myeloma. Georgian medical news, (326), 18-22.

Del Pinto, R., & Ferri, C. (2018). Inflammation-Accelerated Senescence and the Cardiovascular System: Mechanisms and Perspectives. International journal of molecular sciences, 19(12), 3701. https://doi.org/10.3390/ijms19123701

FDA. (n.d.). 510(k) Substantial equivalence determination decision summary (No K093758). http://www.accessdata.fda.gov/cdrh_docs/reviews/K093758.pdf

Syvolap, V. D., & Lashkul, D. A. (2014). Vzaiemozviazky mizh rivnem markeriv fibrozu ST2, halektynu-3, strukturno-funktsionalnymy parametramy livoho shlunochka ta funktsiieiu nyrok pry khronichnii sertsevii nedostatnosti ishemichnoho henezu [The relationship between the level of markers of fibrosis ST2, galectin-3, structural, functional parameters of the left ventricle and renal function in patients with ischemic chronic heart failure]. Zaporozhye medical journal, (5), 13-17. [in Ukrainain].

Lok, D. J., Lok, S. I., Bruggink-André de la Porte, P. W., Badings, E., Lipsic, E., van Wijngaarden, J., de Boer, R. A., van Veldhuisen, D. J., & van der Meer, P. (2013). Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clinical research in cardiology, 102(2), 103-110. https://doi.org/10.1007/s00392-012-0500-y

Meijers, W. C., Januzzi, J. L., deFilippi, C., Adourian, A. S., Shah, S. J., van Veldhuisen, D. J., & de Boer, R. A. (2014). Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. American heart journal, 167(6), 853-60.e4. https://doi.org/10.1016/j.ahj.2014.02.011

van der Velde, A. R., Gullestad, L., Ueland, T., Aukrust, P., Guo, Y., Adourian, A., Muntendam, P., van Veldhuisen, D. J., & de Boer, R. A. (2013). Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circulation. Heart failure, 6(2), 219-226. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000129

Chen, A., Hou, W., Zhang, Y., Chen, Y., & He, B. (2015). Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. International journal of cardiology, 182, 168-170. https://doi.org/10.1016/j.ijcard.2014.12.137

Weir, R. A., Petrie, C. J., Murphy, C. A., Clements, S., Steedman, T., Miller, A. M., McInnes, I. B., Squire, I. B., Ng, L. L., Dargie, H. J., & McMurray, J. J. (2013). Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circulation. Heart failure, 6(3), 492-498. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000146

Thijssen, V. L., Heusschen, R., Caers, J., & Griffioen, A. W. (2015). Galectin expression in cancer diagnosis and prognosis: A systematic review. Biochimica et biophysica acta, 1855(2), 235-247. https://doi.org/10.1016/j.bbcan.2015.03.003

Felker, G. M., Fiuzat, M., Shaw, L. K., Clare, R., Whellan, D. J., Bettari, L., Shirolkar, S. C., Donahue, M., Kitzman, D. W., Zannad, F., Piña, I. L., & O'Connor, C. M. (2012). Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circulation. Heart failure, 5(1), 72-78. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963637

##submission.downloads##

Опубліковано

2022-11-09

Номер

Розділ

Огляд